Response
Sharmaand colleagues provide a thoughtful discussion of one way to reconcile low cardiac parvovirus B19 (PVB19) loads with clinically significant cardiac dysfunction, with regard to our recent article in Circulation. 1 We fully agree that cross-reactive humoral and/or cellular immune reactions against, for example, cellular golgin-160 and parvoviral VP1/2 surface protein may have the potential to incite a chronic autoimmune process involved in the pathogenesis of PVB19-associated cardiac dysfunction. A search for anti-PVB19 VP1/2 proteins in the patients' sera as well as competition ELISA to detect molecular mimicry seems worthwhile. We would like to emphasize, however, that alternative/additional approaches may explain clinical disease at low virus load. First, chronic low level transcription of virusencoded multifunctional proteins such as NS1 may dysregulate or reprogram sensitive cardiac signaling pathways in such a way that insidiously progressive cardiac dysfunction ensues. It has been shown that genetic dysfunction of such pathways may result not only in gross morphological anomalies of the heart but also in more subtle functional disturbances. A genome-wide screening for the possible induction of such disturbances in PVB19infected cardiovascular cells may be helpful to solve this question. Second, the time course to clinically apparent cardiac dysfunction may be discontinuous in the following sense: Any chronic low virus load may be intermittently enhanced by Ն1 order of magnitude when co-infection with a "secondary" virus occurs, which provides helper functions in trans for the "primary" parvovirus. We are investigating this scenario by evaluating the time course of clinical disease in patients harboring Ն2 cardiotropic viruses, as described in Kühl et al. 2 In summary, all of the above approaches may shed light on the molecular links between PVB19 infections and human heart disease.
